GlassScriptPhysician profile
York Sing Chan
NPI 1891010286
$5,096.67
in general payments reported to CMS, 2019-2025
23 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $128 · 2021: $257 · 2022: $602 · 2023: $1,339 · 2024: $1,327 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.19 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Gilead Sciences, INC. | $832.88 | 2019-2025 | |
| Lilly USA, LLC | $457.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $379.19 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $365.85 | 2022-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $331.97 | 2019-2023 | |
| Novo Nordisk INC | $267.97 | 2022-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $264.41 | 2023-2025 | Nexletol |
| Pfizer INC. | $216.55 | 2022-2025 | |
| Exact Sciences Corporation | $213.18 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.63 | 2023-2024 | Trulance, Xifaxan |
| Arbor Pharmaceuticals, INC. | $109.76 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $86.17 | 2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $57.52 | 2022 | |
| Genzyme Corporation | $49.59 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.23 | 2022-2024 | Eliquis, Camzyos |
| Abbvie INC. | $41.32 | 2025 | |
| Phathom Pharmaceuticals, INC. | $37.05 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $25.00 | 2025 | Symbravo |
| Hikma Pharmaceuticals USA | $21.51 | 2022 | |
| Shield Therapeutics INC | $20.21 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.37 | 2024 | Jardiance |
| Ibsa Pharma INC. | $17.65 | 2023 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw York Sing Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.